Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML.
Pfeiffer T, Li Y, Ashcraft E, Karol SE, Rubnitz JE, Epperly R, Madden R, Mamcarz E, Obeng E, Qudeimat A, Sharma A, Srinivasan A, Suliman A, Talleur AC, Velasquez MP, Gottschalk S, Triplett BM, Naik S. Pfeiffer T, et al. Among authors: rubnitz je. Bone Marrow Transplant. 2023 Mar;58(3):328-331. doi: 10.1038/s41409-022-01877-2. Epub 2022 Nov 29. Bone Marrow Transplant. 2023. PMID: 36443431 No abstract available.
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.
Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K, Rubnitz JE, Sandlund JT, Ribeiro RC, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Handgretinger R, Laver JH, Pui CH. Leung W, et al. Among authors: rubnitz je. Blood. 2011 Jul 14;118(2):223-30. doi: 10.1182/blood-2011-01-333070. Epub 2011 May 25. Blood. 2011. PMID: 21613256 Free PMC article.
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.
Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Shook D, Rubnitz JE, Sandlund JT, Jeha S, Inaba H, Ribeiro RC, Handgretinger R, Laver JH, Campana D. Leung W, et al. Among authors: rubnitz je. Blood. 2012 Jul 12;120(2):468-72. doi: 10.1182/blood-2012-02-409813. Epub 2012 Apr 19. Blood. 2012. PMID: 22517895 Free PMC article.
Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.
Karol SE, Coustan-Smith E, Cao X, Shurtleff SA, Raimondi SC, Choi JK, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D, Inaba H. Karol SE, et al. Among authors: rubnitz je. Br J Haematol. 2015 Jan;168(1):94-101. doi: 10.1111/bjh.13107. Epub 2014 Aug 28. Br J Haematol. 2015. PMID: 25164427 Free PMC article.
Natural killer cell therapy in children with relapsed leukemia.
Rubnitz JE, Inaba H, Kang G, Gan K, Hartford C, Triplett BM, Dallas M, Shook D, Gruber T, Pui CH, Leung W. Rubnitz JE, et al. Pediatr Blood Cancer. 2015 Aug;62(8):1468-72. doi: 10.1002/pbc.25555. Epub 2015 Apr 30. Pediatr Blood Cancer. 2015. PMID: 25925135 Free PMC article.
Genetics of pleiotropic effects of dexamethasone.
Ramsey LB, Pounds S, Cheng C, Cao X, Yang W, Smith C, Karol SE, Liu C, Panetta JC, Inaba H, Rubnitz JE, Metzger ML, Ribeiro RC, Sandlund JT, Jeha S, Pui CH, Evans WE, Relling MV. Ramsey LB, et al. Among authors: rubnitz je. Pharmacogenet Genomics. 2017 Aug;27(8):294-302. doi: 10.1097/FPC.0000000000000293. Pharmacogenet Genomics. 2017. PMID: 28628558 Free PMC article.
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
Nguyen R, Wu H, Pounds S, Inaba H, Ribeiro RC, Cullins D, Rooney B, Bell T, Lacayo NJ, Heym K, Degar B, Schiff D, Janssen WE, Triplett B, Pui CH, Leung W, Rubnitz JE. Nguyen R, et al. Among authors: rubnitz je. J Immunother Cancer. 2019 Mar 20;7(1):81. doi: 10.1186/s40425-019-0564-6. J Immunother Cancer. 2019. PMID: 30894213 Free PMC article. Clinical Trial.
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
Karol SE, Alexander TB, Budhraja A, Pounds SB, Canavera K, Wang L, Wolf J, Klco JM, Mead PE, Das Gupta S, Kim SY, Salem AH, Palenski T, Lacayo NJ, Pui CH, Opferman JT, Rubnitz JE. Karol SE, et al. Among authors: rubnitz je. Lancet Oncol. 2020 Apr;21(4):551-560. doi: 10.1016/S1470-2045(20)30060-7. Epub 2020 Mar 11. Lancet Oncol. 2020. PMID: 32171069 Free PMC article. Clinical Trial.
248 results